Ratings Huaxia Eye Hospital Group Co.,Ltd.

Equities

301267

CNE100005WL5

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-26 pm EDT			5-day change	1st Jan Change
24.09 ^CNY	+0.12%		-6.41%	-24.93%

Apr. 30	Huaxia Eye Hospital Group Co.,Ltd. agreed to acquire Xiamen Huaxia Juxin No. 1 Investment Consulting Co., Ltd. from Xiamen Huaxia Juxin No. 1 Investment Partnership Enterprise (Limited Partnership) and Nanjing Xinke Dongzheng 01 Venture Capital Partnership Enterprise (Limited Partnership) for approximately CNY 500 million.	CI
Apr. 26	Huaxia Eye Hospital Group Co.,Ltd. Proposes Final Cash Dividend for 2023	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company returns high margins, thereby supporting business profitability.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

With a 2024 P/E ratio at 24.39 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last few months, analysts have been revising downwards their earnings forecast.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HUAXIA EYE HOSPITAL GROUP CO.,LTD.	-24.93%	2.78B		-
AGILON HEALTH, INC.	-51.47%	2.5B		C-
EUROEYES INTERNATIONAL EYE CLINIC LIMITED	-1.15%	218M		-
AIRSCULPT TECHNOLOGIES, INC.	-53.14%	202M		-
MEDSCI HEALTHCARE HOLDINGS LIMITED	-42.98%	189M	-	-
AESTHETIC CONNECT	-33.52%	114M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes